Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Biography

  • Issuer counsel in a $16.2 million private placement offering of ordinary shares and warrants by a late-stage biopharma company aiming to improve surgical outcomes
  • Issuer counsel in multiple equity capital markets financings, including a $16 million initial public offering of ordinary shares and warrants and a $2 million public offering of ordinary shares by a technology growth company specializing in AI-powered touchless sensing wearables
  • Issuer counsel in $4 million public offering of ordinary shares and warrants (January 2024); $2.5 million private placement of ordinary shares and warrants (June 2023); $9.35 million At-The-Market (ATM) public offering (June 2023); and $15 million private placement and concurrent listing of ordinary shares on Nasdaq (May 2022) by a clean-energy company that provides thermal energy storage systems and services that allow customers to decarbonize their operations
  • Issuer counsel in listing of ordinary shares on Nasdaq (August 2021); $17 million underwritten public offering (December 2021); $14.5 million public offering (December 2022); and $9.7 million At-The-Market (ATM) public offering (January 2024) by a developer of cryoablation technology that destroys tumors by freezing them without the need for surgery, in connection with its: listing of ordinary shares on Nasdaq (August 2021); $17 million underwritten public offering (December 2021); $14.5 million public offering (December 2022); and $9.7 million At-The-Market (ATM) Offering (January 2024)
  • Issuer counsel in multiple equity capital markets financings, including $28 million At-The-Market (ATM) public offering of common stock (June 2021); $100 million At-The-Market (ATM) public offering of common stock (July 2021); $100 million At-The-Market (ATM) public offering of common stock (September 2021); and $50 million Registered Direct Offering (November 2021) by a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems
  • Issuer counsel in multiple equity capital markets financings, including $7.5 At-The-Market (ATM) public offering of common stock (December 2023) and $50 million At-The-Market (ATM) public offering of common stock by a clinical-stage company advancing novel natural and engineered phage therapies
  • Issuer counsel in a $28.6 private placement of preferred stock of a Nasdaq listed leading global digital health company with mobile health and big data solutions
  • Placement agent counsel in a $16 million offering of common stock and warrants by a company that markets and sells a wide variety of complementary products and services to customers operating in the regulated medical and recreational cannabis and cannabidiol (CBD) industries
  • Issuer counsel in a $21 million offering of common stock and warrants by a leading developer of placenta-based cell therapy products
  • Issuer counsel in a $56 million Series A financing of a private biotech company committed to developing vaccines against pathogens acquired by mucosal infection
  • Issuer counsel in a $50 million private placement of preferred stock by a private clinical-stage biopharmaceutical company focused on developing and commercializing novel, locally administered therapies
  • Underwriter counsel in a $16 million public offering by a late-stage biotechnology company developing immunotherapies that enlist the body's own immune system to fight cancer
  • Underwriter counsel in an $8 million public offering of common stock and warrants by an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers
  • Underwriter counsel in a $7 million offering of common stock and warrants by a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products
  • Issuer counsel in a $15.5 million initial public offering of ordinary shares and warrants by a B2B provider of artificial intelligence accelerated video solutions for edge platforms
  • Issuer counsel in a $15.5 million initial public offering of ordinary shares and warrants by a data-driven e-commerce company operating on the Amazon Marketplace
  • Issuer counsel in a $12 million initial public offering of ordinary shares by a an agri-food-tech company focused on developing and selling eco-friendly products
  • Issuer counsel in a $15 million initial public offering of ordinary shares and warrants by a telehealth, medical device, and remote patient monitoring company

Matters

  • Issuer counsel in a $16.2 million private placement offering of ordinary shares and warrants by a late-stage biopharma company aiming to improve surgical outcomes
  • Issuer counsel in multiple equity capital markets financings, including a $16 million initial public offering of ordinary shares and warrants and a $2 million public offering of ordinary shares by a technology growth company specializing in AI-powered touchless sensing wearables
  • Issuer counsel in $4 million public offering of ordinary shares and warrants (January 2024); $2.5 million private placement of ordinary shares and warrants (June 2023); $9.35 million At-The-Market (ATM) public offering (June 2023); and $15 million private placement and concurrent listing of ordinary shares on Nasdaq (May 2022) by a clean-energy company that provides thermal energy storage systems and services that allow customers to decarbonize their operations
  • Issuer counsel in listing of ordinary shares on Nasdaq (August 2021); $17 million underwritten public offering (December 2021); $14.5 million public offering (December 2022); and $9.7 million At-The-Market (ATM) public offering (January 2024) by a developer of cryoablation technology that destroys tumors by freezing them without the need for surgery, in connection with its: listing of ordinary shares on Nasdaq (August 2021); $17 million underwritten public offering (December 2021); $14.5 million public offering (December 2022); and $9.7 million At-The-Market (ATM) Offering (January 2024)
  • Issuer counsel in multiple equity capital markets financings, including $28 million At-The-Market (ATM) public offering of common stock (June 2021); $100 million At-The-Market (ATM) public offering of common stock (July 2021); $100 million At-The-Market (ATM) public offering of common stock (September 2021); and $50 million Registered Direct Offering (November 2021) by a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems
  • Issuer counsel in multiple equity capital markets financings, including $7.5 At-The-Market (ATM) public offering of common stock (December 2023) and $50 million At-The-Market (ATM) public offering of common stock by a clinical-stage company advancing novel natural and engineered phage therapies
  • Issuer counsel in a $28.6 private placement of preferred stock of a Nasdaq listed leading global digital health company with mobile health and big data solutions
  • Placement agent counsel in a $16 million offering of common stock and warrants by a company that markets and sells a wide variety of complementary products and services to customers operating in the regulated medical and recreational cannabis and cannabidiol (CBD) industries
  • Issuer counsel in a $21 million offering of common stock and warrants by a leading developer of placenta-based cell therapy products
  • Issuer counsel in a $56 million Series A financing of a private biotech company committed to developing vaccines against pathogens acquired by mucosal infection
  • Issuer counsel in a $50 million private placement of preferred stock by a private clinical-stage biopharmaceutical company focused on developing and commercializing novel, locally administered therapies
  • Underwriter counsel in a $16 million public offering by a late-stage biotechnology company developing immunotherapies that enlist the body's own immune system to fight cancer
  • Underwriter counsel in an $8 million public offering of common stock and warrants by an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers
  • Underwriter counsel in a $7 million offering of common stock and warrants by a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products
  • Issuer counsel in a $15.5 million initial public offering of ordinary shares and warrants by a B2B provider of artificial intelligence accelerated video solutions for edge platforms
  • Issuer counsel in a $15.5 million initial public offering of ordinary shares and warrants by a data-driven e-commerce company operating on the Amazon Marketplace
  • Issuer counsel in a $12 million initial public offering of ordinary shares by a an agri-food-tech company focused on developing and selling eco-friendly products
  • Issuer counsel in a $15 million initial public offering of ordinary shares and warrants by a telehealth, medical device, and remote patient monitoring company

Matters

Neural Input Technology Company, Wearable Devices Ltd. IPO

Sullivan represented Wearable Devices Ltd., a growth company developing a non-invasive neural input interface technology in the form of a wrist wearable band for controlling digital devices using subtle finger movements for B2B and B2C customers, in its $16 million initial public offering. Wearable Devices is based in Israel and aims to create a world in which the user’s hand becomes a universal input device for touchlessly interacting with technology, and that their technology is setting the standard input interface for the Metaverse.

Howard E. Berkenblit, Oded Har-Even, Tamilla Nurizada and Ilana Neck Levin

Thermal Energy Storage Company Shares to Commence Trading on Nasdaq

Sullivan advised Brenmiller Energy Ltd., a designer, builder and operator of thermal energy storage systems, in its $15 million private placement of ordinary shares and uplisting of ordinary shares to Nasdaq. The Company develops storage-based generation systems that combines thermal storage, inherent heat exchanging, and inherent steam generation in one unit.

Oded Har-Even, Reut Alfiah, Eric Victorson, Gal Cohen, Ilana Neck Levin and Emily A. Goldschmidt

Solar Panel On Field Against Sky